|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/403 | (2006.01) |
| A61K 31/403 | (2013.01) | ||
| A61K 9/00 | (2006.01) | ||
| A61P 1/04 | (2018.01) | ||
| A61K 31/496 | (2013.01) | ||
| A61K 31/496 | (2006.01) | ||
| A61K 31/192 | (2013.01) | ||
| A61P 1/04 | (2006.01) | ||
| G01N 33/50 | (2006.01) | ||
| A61K 31/7048 | (2013.01) | ||
| A61K 31/192 | (2006.01) | ||
| A61K 31/565 | (2013.01) | ||
| A61K 31/195 | (2006.01) | ||
| A61K 31/566 | (2013.01) | ||
| A61K 31/4196 | (2006.01) | ||
| A61K 31/195 | (2013.01) | ||
| A61K 31/49 | (2006.01) | ||
| A61K 31/49 | (2013.01) | ||
| A61K 31/565 | (2006.01) | ||
| A61K 31/4196 | (2013.01) | ||
| A61K 31/566 | (2006.01) | ||
| G01N 33/6872 | (2013.01) | ||
| A61K 31/7048 | (2006.01) | ||
| G01N2800/52 | (2013.01) | ||
| A61K 9/20 | (2006.01) | ||
| G01N2800/065 | (2013.01) | ||
| A61K 9/48 | (2006.01) | ||
| A61K 9/2018 | (2013.01) | ||
| G01N 33/68 | (2006.01) | ||
| A61K 9/48 | (2013.01) | ||
| A61K 9/2054 | (2013.01) |
| (11) | Number of the document | 3801459 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19739424.0 |
| Date of filing the European patent application | 2019-06-05 | |
| (97) | Date of publication of the European application | 2021-04-14 |
| (45) | Date of publication and mention of the grant of the patent | 2024-08-07 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2019/035662 |
| Date | 2019-06-05 |
| (87) | Number | WO 2019/236757 |
| Date | 2019-12-12 |
| (30) | Number | Date | Country code |
| 201862681426 P | 2018-06-06 | US | |
| 201862746946 P | 2018-10-17 | US | |
| 201962850470 P | 2019-05-20 | US |
| (72) |
CHRISTOPHER, Ronald J. , US
SADEQUE, Abu J.M. , US
|
| (73) |
Arena Pharmaceuticals, Inc. ,
66 Hudson Boulevard East, New York, NY 10001-2192,
US
|
| (54) | METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR |
| METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR |